- 英文名称
- Obeticholic acid
- 分子式
- C26H44O4
- 分子量
- 420.63
- 中文别名
- (R)-4-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-乙基-3,7-二羟基-10,13-二甲基十六氢-1H-环戊二烯并[a]菲-17-基)戊酸; 6-乙基鹅去氧胆酸; (R)-4-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; INT-747; (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; 6α-ethyl-chenodeoxycholic acid; 6alpha-Ethyl-chenodeoxycholic acid; 6-Ethylchenodeoxycholic acid; 6-ECDCA; OCA; (3α,5β,6α,7α,8ξ)-6-Ethyl-3,7-dihydroxycholan-24-oic acid; 3α,7α-Dihydroxy-6α-ethyl-5β-cholan-24-oic acid
- 用途
- (R)-4-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-乙基-3,7-二羟基-10,13-二甲基十六氢-1H-环戊二烯并[a]菲-17-基)戊酸（奥贝胆酸）是法尼酯衍生物X受体（FXR）的天然配体；属法尼醇X受体激动剂，通过活化法尼醇X受体，间接抑制细胞色素7A1（CYP7A1）的基因表达，抑制胆酸合成，用于治疗原发性胆汁性肝硬化（PBC）和非酒精性脂肪性肝病（NAFLD）；改善胰岛素抵抗；改善肝脏炎症和纤维化水平；改善蛋白尿和肾脏结构的改变，并调节肾脏炎症和氧化应激；降低门静脉压力；抑制自噬。
